EZH2 and neoplasm: In tumoral mouse models, tumor-infiltrating CD8+ T-cells expressed EZH2, and due to the upregulation of BCL-2, exhibited an anti-apoptotic feature associated with increased survival [234], which is abolished in EZH2-deficient CD8+ T-cells [235] (Figure 4B).